Remedy Pharmaceuticals
No bio yet
This person is not in the org chart
This person is not in any teams
Remedy Pharmaceuticals
Remedy Pharmaceuticals, Inc. develops small molecule drugs that target NCCa-ATP channels in acute central nervous system injuries, including traumatic brain injuries, strokes, and spinal cord injuries. Its RP-1127 is an intravenous version of glyburide, an inhibitor of NCCa-ATP channels that acts through antagonism of the type-1 sulfonylureareceptor. The company was founded in 2004 and is based in New York, New York.